ALX Oncology Holdings Inc. (ALXO)
$
1.42
+0.05 (3.52%)
Key metrics
Financial statements
Free cash flow per share
-1.9797
Market cap
77 Million
Price to sales ratio
88.6977
Debt to equity
0.2512
Current ratio
4.5234
Income quality
0.9049
Average inventory
0
ROE
-1.1567
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on developing innovative therapies for cancer patients. Its lead product candidate, ALX148, is a CD47 blocking therapeutic currently undergoing Phase 1b/2 clinical trials targeting myelodysplastic syndromes, acute myeloid leukemia, non-Hodgkin's lymphoma, and various solid tumors, including head and neck squamous cell carcinoma and HER2-positive gastric and breast cancers. Additionally, the company is advancing ALTA-002, a SIRPa TRAAC designed to engage both innate and adaptive immune responses against cancer. The net total of other income and expenses is $7,617,000.00 reflecting non-core financial activities. The weighted average number of diluted shares outstanding is 52,174,904.00 indicating potential dilution effects. The earnings per share (EPS) is reported at -$2.58 showcasing the company's profitability on a per-share basis. In the fiscal year 2024 the company reported depreciation and amortization expenses of $872,000.00 highlighting the wear and tear of its assets. ALX Oncology has partnered with Merck for a Phase 2 trial assessing ALX148's efficacy in combination with pembrolizumab in head and neck cancer patients, and with Zymeworks on a Phase 1 trial evaluating ALX148 alongside the HER2-targeting bispecific antibody zanidatamab. There is also collaboration with Tallac Therapeutics for the development and commercialization of a novel class of cancer immunotherapeutics, backed by license agreements with Selexis SA and Crystal Bioscience, Inc. Founded in 2015 and headquartered in South San Francisco, California, the company is carving out its niche in the competitive oncology landscape. The stock is affordable at $1.21 making it an appealing option for budget-conscious investors. With an average trading volume of 492,247.00 the stock indicates moderate liquidity, allowing for flexible buying and selling. ALX Oncology Holdings Inc., with a market capitalization of $76,989,561.00 is identified as a small-cap player within the Biotechnology industry, contributing significantly to the overall market dynamics. It operates within the Healthcare sector, where it plays a vital role in driving innovation and fostering growth.
Is ALX Oncology Holdings Inc. (ALXO) a good investment?
Investing in ALX Oncology Holdings Inc. (ALXO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is ALX Oncology Holdings Inc. (ALXO)'s stock forecast?
Analysts predict ALX Oncology Holdings Inc. stock to fluctuate between $0.40 (low) and $2.27 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is ALX Oncology Holdings Inc.'s market capitalization?
As of 2025-12-05, ALX Oncology Holdings Inc.'s market cap is $76,989,561, based on 54,218,001 outstanding shares.
How does ALX Oncology Holdings Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, ALX Oncology Holdings Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy ALX Oncology Holdings Inc. (ALXO) stock?
To buy ALX Oncology Holdings Inc. (ALXO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALXO. Place an order (Market, Limit, etc.).
What is the best time to invest in ALX Oncology Holdings Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did ALX Oncology Holdings Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$2.58 | Growth: -31.02%.
Where can I find ALX Oncology Holdings Inc.'s investor relations reports?
Visit https://www.alxoncology.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for ALX Oncology Holdings Inc.?
You can explore historical data from here
What is the all-time high and low for ALX Oncology Holdings Inc. stock?
All-time high: $81.19 (2021-09-17) | All-time low: $0.40 (2025-06-27).
What are the key trends affecting ALX Oncology Holdings Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
18 days ago
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in both the Jefferies Global Healthcare Conference in London and Piper Sandler 37th Annual Global Healthcare Conference in New York.
seekingalpha.com
a month ago
ALX Oncology Holdings Inc. ( ALXO ) Q3 2025 Earnings Call November 7, 2025 8:30 AM EST Company Participants Jason Lettmann - CEO & Director Barbara Klencke Conference Call Participants John Mills - ICR Inc. Daniel Bronder Jiale Song - Jefferies LLC, Research Division Samuel Slutsky - LifeSci Capital, LLC, Research Division Presentation Jason Lettmann CEO & Director Thanks, everyone, and welcome to our Q3 2025 results. I appreciate everybody spending some time with us this morning, and I'm looking forward to this update.
globenewswire.com
a month ago
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update.
defenseworld.net
a month ago
ALX Oncology (NASDAQ: ALXO - Get Free Report) is expected to be posting its Q3 2025 results before the market opens on Friday, November 7th. Analysts expect ALX Oncology to post earnings of ($0.37) per share for the quarter. Interested persons may review the information on the company's upcoming Q3 2025 earningreport for the latest details
globenewswire.com
a month ago
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its third quarter 2025 financial results and provide a business update on Friday, November 7th, 2025, before market open.
globenewswire.com
a month ago
-Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors
globenewswire.com
2 months ago
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced updated data from its Phase 2 ASPEN-06 (NCT05002127) trial will be presented during a poster session at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting taking place November 5–9, 2025, in National Harbor, Maryland. The Phase 2 trial evaluated evorpacept, the Company's lead therapeutic candidate, in combination with HERCEPTIN® (trastuzumab), CYRAMZA® (ramucirumab) and paclitaxel, for patients with previously treated HER2-positive advanced gastric cancer (GC) and gastroesophageal junction (GEJ) cancer.
globenewswire.com
3 months ago
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced the appointment of Dr. Klencke to the role of Interim Chief Medical Officer (CMO) on a full-time basis. Dr. Alan Sandler is departing from the role of CMO and will return to his former position on the ALX Oncology Board of Directors (BOD), where he previously served.
globenewswire.com
3 months ago
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in both the Cantor Global Healthcare Conference 2025 and H.C. Wainwright 27th Annual Global Investment Conference in New York.
globenewswire.com
4 months ago
- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window -First-in-human trial of ALX2004 builds upon body of positive preclinical data demonstrating dose dependent anti-tumor activity and favorable safety profile -Initial safety data anticipated in first half 2026 SOUTH SAN FRANCISCO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the"Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that the first patient has been dosed in the Company's Phase 1 clinical trial for ALX2004, a potential best- and first-in-class, epidermal growth factor receptor (EGFR) ADC that is being studied for the treatment of EGFR-expressing solid tumors.
See all news
